22. Value of ca125, he4, roma index, copenhagen index in predicting ovarian cancer at Hanoi Medical University Hospital
Main Article Content
Abstract
Ovarian cancer (OC) is the most common genital cancer and one of the leading causes of cancer death in women worldwide. Until now, up to 70% of cancer patients are detected at a late stage, leading to many difficulties in treatment and poor prognosis. Consequently, the use of biomarkers such as CA125, HE4 tests, RMI index, ROMA index, CPH-I index to support the diagnosis of OC is important in clinical practice. In this cross-sectional descriptive study, we determined the value of CA125, HE4, ROMA index, CPH-I index on 78 patients for the diagnosis of OC at Hanoi Medical University Hospital from 2020 - 2021. Based on the results of post-operative pathology and definitive diagnosis, out of a total of 78 subjects, 20 subjects had no detected tumor, 30 subjects were diagnosed with benign ovarian tumors and 28 subjects were diagnosed with ovarian tumors. The results show that the sensitivity and specificity of CA125 test are 48.1% and 94%; HE4 test are 42.9% and 98%. Furthermore, the use of the ROMA index gave a better value than the CA125 or HE4 test alone with 55.6% sensitivity and specificity 98%. The value of the CPH-I index is also recorded with the area under the ROC curve 0,906, the sensitivity and specificity are 70.4% and 96%.
Article Details
Keywords
Ovarian cancer, CA125, HE4, ROMA, CPH-I
References
2. Nguyễn TN, Nguyễn QT, Nguyễn TH, et al. Nghiên cứu giá trị của CA125, HBE4 trong chẩn đoán u nhầy buồng trứng tại Bệnh viện Phụ sản Trung ương trong 5 năm từ 2016 đến 2020. VMJ. 2021; 504(2).
3. Cesare Romagnolo, Antonette E Leon, Aline S C Fabricio. HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study. Gynecol Oncol. 2016; 141(2): 303-311.
4. Karlsen MA, Sandhu N, Høgdall C, et al. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass. Gynecologic Oncology. 2012; 127(2): 379-383.
5. Lee YJ, Kim YM, Kang JS, et al. Comparison of Risk of Ovarian Malignancy Algorithm and cancer antigen 125 to discriminate between benign ovarian tumor and early-stage ovarian cancer according to imaging tumor subtypes. Oncol Lett. 2020; 20(1): 931-938.
6. Võ VK, Nguyễn VQH. Nghiên cứu giá trị của HE4, CA-125, thuật toán nguy cơ ác tính buồng trứng (ROMA) trong chẩn đoán trước mổ ung thư buồng trứng. Tạp chí Phụ sản. 2018; 16(2): 79-85.
7. Giảng Thị Mộng Huyền, Lê Xuân Trường, Nguyễn Thị Băng Sương, et al. Giá trị xét nghiệm CA125 trong chẩn đoán ung thư biểu mô buồng trứng. Tạp chí Y học TPHCM. 2020; 24(1): 142-145.
8. Phạm Thị Diệu Hà. Nhận xét giá trị CA125, HE4 và Test ROMA trong theo dõi điều trị ung thư buồng trứng. Tạp chí Ung thư học Việt Nam. 2019; 2: 403-410.
9. Z G Dikmen. Diagnostic performances of CA125, HE4, and ROMA index in ovarian cancer Eur J Gynaecol Oncol. 2015; 36(4): 457-62.
10. Trần Doãn Tú. So sánh chỉ số Copenhagen với chỉ số ROMA trong dự báo tiền phẫu ung thư buồng trứng. Tạp chí Phụ sản. 2020; 18(3): 41-48.